[HTML][HTML] Bone metastasis in prostate cancer: bone scan versus PET imaging
N Mohseninia, N Zamani-Siahkali, S Harsini… - Seminars in Nuclear …, 2023 - Elsevier
Prostate cancer is the second most common cause of malignancy among men, with bone
metastasis being a significant source of morbidity and mortality in advanced cases …
metastasis being a significant source of morbidity and mortality in advanced cases …
[HTML][HTML] A Review on the Current State and Future Perspectives of [99mTc]Tc-Housed PSMA-i in Prostate Cancer
S Brunello, N Salvarese, D Carpanese, C Gobbi… - Molecules, 2022 - mdpi.com
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of …
nuclear molecular imaging as an excellent target for both the diagnosis and therapy of …
[HTML][HTML] Radiomics and Artificial Intelligence in Radiotheranostics: a review of applications for Radioligands Targeting somatostatin receptors and prostate-specific …
E Yazdani, P Geramifar, N Karamzade-Ziarati… - Diagnostics, 2024 - mdpi.com
Radiotheranostics refers to the pairing of radioactive imaging biomarkers with radioactive
therapeutic compounds that deliver ionizing radiation. Given the introduction of very …
therapeutic compounds that deliver ionizing radiation. Given the introduction of very …
[HTML][HTML] Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate …
R Manafi-Farid, S Harsini, B Saidi… - European Journal of …, 2021 - Springer
Background Prostate cancer (PC) is one of the most common cancers in men. Although the
overall prognosis is favorable, the management of metastatic castration-resistant prostate …
overall prognosis is favorable, the management of metastatic castration-resistant prostate …
Delayed imaging improves lesion detectability in [99mTc] Tc-PSMA-I&S SPECT/CT in recurrent prostate cancer
C Berliner, L Steinhelfer, M Chantadisai… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Our objective was to compare the ability to detect histopathologically confirmed lymph node
metastases by early and delayed [99mTc] Tc-PSMA-I&S SPECT/CT in early biochemically …
metastases by early and delayed [99mTc] Tc-PSMA-I&S SPECT/CT in early biochemically …
[HTML][HTML] Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends
R Manafi-Farid, S Ranjbar, Z Jamshidi Araghi, J Pilz… - Cancers, 2021 - mdpi.com
Simple Summary Accurate primary staging for determining the extent of prostate cancer is
crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still …
crucial for planning treatment in high-risk patients for distant metastases. Recurrence is still …
[HTML][HTML] Fluorescent imaging for cancer therapy and cancer gene therapy
Y Woo, S Chaurasiya, M O'Leary, E Han… - Molecular Therapy …, 2021 - cell.com
The translation of laboratory science into effective clinical cancer therapy is gaining
momentum more rapidly than any other time in history. Understanding cancer cell-surface …
momentum more rapidly than any other time in history. Understanding cancer cell-surface …
[HTML][HTML] Comparing 99mTc-PSMA to 99mTc-MDP in prostate cancer staging of the skeletal system
Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging... : Clinical Nuclear
Medicine Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal …
Medicine Comparing 99mTc-PSMA to 99mTc-MDP in Prostate Cancer Staging of the Skeletal …
[HTML][HTML] The efficacy of 99mTc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer
T Wang, L Zhao, W Qiao, N Sun, J Zhao… - Frontiers in …, 2023 - frontiersin.org
Purpose Compared with PET/CT or PET/MRI, SPECT/CT is cheaper and more readily
accessible. This study was designed to investigate the efficacy of 99mTc-HYNIC-PSMA …
accessible. This study was designed to investigate the efficacy of 99mTc-HYNIC-PSMA …
[HTML][HTML] The application of radiolabeled targeted molecular probes for the diagnosis and treatment of prostate cancer
L Cheng, T Yang, J Zhang, F Gao… - Korean Journal of …, 2023 - ncbi.nlm.nih.gov
Radiopharmaceuticals targeting prostate-specific membrane antigens (PSMA) are essential
for the diagnosis, evaluation, and treatment of prostate cancer (PCa), particularly metastatic …
for the diagnosis, evaluation, and treatment of prostate cancer (PCa), particularly metastatic …